The clinical features of dermatomyositis in a South Australian population

APLAR Journal of Rheumatology

Volumn 10, Issue 2, 2007, Pages 86-93

  Limaye, Vidya ^a   Blumbergs, Peter ^b   Scott, Grace ^b   Roberts Thomson, Peter ^c  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b HANSON INSTITUTE   (Australia)

^c FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

Anti Jo 1 antibody; Creatine kinase; Dermatomyositis; Infections; Malignancy

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; ANTIBODY; ANTINUCLEAR ANTIBODY; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; INFLUENZA VACCINE; JO 1 ANTIBODY; LACTATE DEHYDROGENASE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; AUSTRALIA; CLINICAL FEATURE; CONTROLLED STUDY; DERMATOMYOSITIS; DISEASE ACTIVITY; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MUSCLE BIOPSY; MYCOPLASMA PNEUMONIA; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM;

EID: 34249746222     PISSN: 02190494     EISSN: 14798077     Source Type: Journal    
DOI: 10.1111/j.1479-8077.2007.00266.x     Document Type: Review

References (43)

1. Mastaglia FL, Phillips BA (2002) Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria. Rheum Dis Clin North Am 28, 723-41.
2. Dalakas MC (1991) Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 325, 1487-98.
3. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292, 344-7.
4. Bohan A, Peter JB, Bowman RL, Pearson CM (1977) Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 56, 255-86.
5. Targoff IN, Reichlin M (1985) The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum 28, 796-803.
6. Zhang Y, LeRoy G, Seelig HP, Lane WS, Reinberg D (1998) The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities. Cell 95, 279-89.
7. Hengstman GJ, Vree Egberts WT, Seelig HP, et al. (2006) Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen. Ann Rheum Dis 65, 242-5.
8. Zampieri S, Ghirardello A, Iaccarino L, Tarricone E, Gambari PF, Doria A (2005) Anti-Jo-1 antibodies. Autoimmunity 38, 73-8.
9. Parodi A, Caproni M, Marzano AV, et al. (2002) Dermatomyositis in 132 patients with different clinical subtypes: Cutaneous signs, constitutional symptoms and circulating antibodies. Acta Derm Venereol 82, 48-51.
10. Rozman B, Bozic B, Kos-Golja M, Plesivcnik-Novljan M, Kvedir T (2000) Immunoserological aspects of idiopathic inflammatory muscle disease. Wien Klin Wochenschr 112, 722-7.
11. Vazquez-Abad D, Rothfield NF (1996) Sensitivity and specificity of anti-Jo-1 antibodies in autoimmune diseases with myositis. Arthritis Rheum 39, 292-6.
12. Tanimoto K, Nakano K, Kano S, et al. (1995) Classification criteria for polymyositis and dermatomyositis. J Rheumatol 22, 668-74. Erratum In: J Rheumatol 1995 Sep; 22 (9): 1807.
13. Hengstman GJD, van Brenk L, Vree Egberts WTM, et al. (2005) High specificity of myositis specific autoantibodies for myositis compared with other neuromuscular disorders. J Neurol 252, 534-7.
14. Targoff IN, Miller FW, Medsger TA Jr, Oddis CV (1997) Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol 9, 527-35.
15. Nirmalananthan N, Holton JL, Hanna MG (2004) Is it really myositis? A consideration of the differential diagnosis. Curr Opin Rheumatol 16, 684-91.
16. Hohlfeld R (2002) Polymyositis and dermatomyositis. In: Karpati G, ed. Structural and Molecular Basis of Skeletal Muscle Diseases, pp. 221-7. ISN. Neuropath Press, Switzerland.
17. Patrick M, Buchbinder R, Jolley D, Dennet X, Buchanan R (1999) Incidence of inflammatory myopathies in Victoria, Australia, and evidence of spatial clustering. J Rheumatol 26, 1094-100.
18. Kass E, Straume S, Munthe E (1978) Dermatomyositis after B.C.G. vaccination. Lancet 1, 772.
19. Kass E, Straume S, Mellbye OJ, Munthe E, Solheim BG (1979) Dermatomyositis associated with BCG vaccination. Scand J Rheumatol 8, 187-91.
20. Albert JM, Ott HJ (1983) Calcifying dermatomyositis following antitetanus vaccination. Arch Intern Med 143, 1457-8.
21. Harland CC, Marsden JR, Vernon SA, Allen BR (1991) Dermatomyositis responding to treatment of associated toxoplasmosis. Br J Dermatol 125, 76-8.
22. Pollock JL (1979) Toxoplasmosis appearing to be dermatomyositis. Arch Dermatol 115, 736-7.
23. Hendrickx GF, Verhage J, Jennekens FG, van Knapen F (1979) Dermatomyositis and toxoplasmosis. Ann Neurol 5, 393-5.
24. Roig Quilis M, Damjanov I (1982) Dermatomyositis as an immunologic complication of toxoplasmosis. Acta Neuropathol (Berl) 58, 183-6.
25. Crowson AN, Magro CM, Dawood MR (2000) A Causal role for parvovirus B19 infection in adult dermatomyositis and other autoimmune syndromes. J Cutan Pathol 27, 505-15.
26. Chevrel G, Calvet A, Belin V, Miossec P (2000) Dermatomyositis associated with the presence of parvovirus B19 DNA in muscles. Rheumatology (Oxford) 39, 1037-9.
27. Pachman LM, Lipton R, Ramsey-Goldman R, et al. (2005) History of infection before the onset of juvenile dermatomyositis: Results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry. Arthritis Rheum 53, 166-72.
28. Lyon MG, Bloch DA, Hollack B, Fries JF (1989) Predisposing factors in polymyositis-dermatomyositis: Results of a nationwide survey. J Rheumatol 16, 1218-24.
29. Gabay C, Gay-Crosier F, Roux-Lombard P, et al. (1994) Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/ dermatomyositis. A biologic marker of disease activity with a possible role in the lack of acute-phase protein response. Arthritis Rheum 37, 1744-51.
30. Tymms KE, Beller EM, Webb J, Schrieber L, Buchanan WW (1990) Correlation between tests of muscle involvement and clinical muscle weakness in polymyositis and dermatomyositis. Clin Rheumatol 9, 523-9.
31. Louthenroo W, Weerayutwattana N, Lertprasertsuke N, Sukitawat W (2002) Serum muscle enzymes, muscle pathology and clinical muscle weakness: correlation in Thai patients with polymyositis/dermatomyositis. J Med Assoc Thai 85, 26-32.
32. Vogels MT, Eling WM, Otten A, van der Meer JW (1995) Interleukin-1 (IL-1) -induced resistance to bacterial infection: Role of the type I IL-1 receptor. Antimicrob Agents Chemother 39, 1744-7.
33. Sigurgeirsson B, Lindelof B, Edhag O, Allander E (1992) Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 6, 326, 363-7.
34. Buchbinder R, Forbes A, Hall S, Dennet X, Giles G (2001) Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med 134, 1087-95.
35. Mebazaa A, Boussen H, Nouira R, et al. (2003) Dermatomyositis and malignancy in Tunisia: A multicenter national retrospective study of 20 cases. J Am Acad Dermatol 48, 530-4.
36. Hill CL, Zhang Y, Sigurgeirsson B, et al. (2001) Frequency of specific cancer types in dermatomyositis and polymyositis: A population-based study. Lancet 13, 357, 96-100.
37. Sparsa A, Liozon E, Herrmann F, et al. (2002) Routine vs extensive malignancy search for adult dermatomyositis and polymyositis: A study of 40 patients. Arch Dermatol 138, 885-90.
38. Burnouf M, Mahe E, Verpillat P, et al. (2003) Cutaneous necrosis is predictive of cancer in adult dermatomyositis. Ann Dermatol Venereol 130, 313-6.
39. Amoura Z, Duhaut P, Huong du LT, et al. (2005) Tumor antigen markers for the detection of solid cancers in inflammatory myopathies. Cancer Epidemiol Biomarkers Prev 14, 1279-82.
40. Cid MC, Grau JM, Casademont J, et al. (1996) Leucocyte/endothelial cell adhesion receptors in muscle biopsies from patients with idiopathic inflammatory myopathies (IIM). Clin Exp Immunol 104, 467-73.
41. Komiya T, Negoro N, Kondo K, Miura K, Hirota Y, Yoshikawa J (2005) Clinical significance of von Willebrand factor in patients with adult dermatomyositis. Clin Rheumatol 24, 352-7.
42. Esmon CT (2005) The interactions between inflammation and coagulation. Br J Haematol 131, 417-30.
43. Esmon CT (2005) Inflammation and coagulation. Hematology 10 (Suppl), 40.